Candidate gene polymorphisms related to lipid metabolism in Asian Indians living in Durban, South Africa

Tanya Maistry, Michelle Gordon, Benn Sartorius & Datshana P. Naidoo

Departments of 1Cardiology, 2Molecular Biology & 3Public Health Medicine, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa

Received July 14, 2016

Background & objectives: Asian Indians have been shown to have a high prevalence of metabolic syndrome (MetS), related to insulin resistance and possibly genetic factors. The aim of this study was to determine the genetic patterns associated with MetS in Asian Indians living in Durban, South Africa.

Methods: Nine hundred and ninety nine participants from the Phoenix Lifestyle Project underwent clinical, biochemical and genetic assessment. MetS was diagnosed according to the harmonized definition. The apolipoprotein A5 Q139X, lipoprotein lipase (LPL) Hinf I, human paraoxonase 1 (PON1) 192Arg/Gln, cholesteryl ester transfer protein (CETP) Taq1B, adiponectin 45T>G and leptin (LEP) 25CAG were genotyped by real-time polymerase chain reaction in participants with and without MetS. Univariate-unadjusted and multivariate-adjusted relations were conducted for all analyses.

Results: The prevalence of MetS was high (49.0%). More females had MetS than males (51.0 vs 42.8%). There was no significant difference in the distribution of genotypes between participants with MetS and those without. Males with the MetS who had the adiponectin TG genotype and human paraoxonase 1 AA genotype were more likely to have reduced high-density lipoprotein cholesterol (HDL-C) (P=0.001) and higher systolic blood pressure (P=0.018), respectively.

Interpretation & conclusions: About half of the Asian Indians living in Phoenix had MetS. No association between the polymorphisms studied and the risk for MetS was observed. The adiponectin TG genotype may be associated with reduced HDL-C and the human paraoxonase 1 AA genotype with hypertension in males. This suggested that lifestyle factors were the major determinant for MetS in this ethnic group and the genetic risk might be related to its component risk factors than to MetS as an entity.

Key words Dyslipidaemia - genotype - hypertension - insulin resistance - metabolic syndrome - single-nucleotide polymorphism

Insulin resistance (IR) and obesity contribute to the development of risk factor clustering in the metabolic syndrome (MetS). Several investigators have examined the prevalence of MetS across different ethnic groups. Certain ethnic groups such as Asian Indians have been found to be more predisposed to developing the MetS1,2. In addition to IR and obesity, early evidence from twin and familial aggregation studies3 has suggested a genetic contribution to the pathogenesis of the MetS. Genome-wide scans have identified various
chromosomal regions with suggestive linkage to the MetS. To date, varying associations have been reported between single-nucleotide polymorphism(s) (SNPs) of certain genes and the MetS. A genetic predisposition might explain the increased susceptibility to cardiovascular disease in South African Indians. This study was undertaken to evaluate SNPs in selected candidate genes associated with lipid and carbohydrate metabolism in Asian Indians living in Durban, South Africa.

**Material & Methods**

All participants from the Phoenix Lifestyle Project (PLP) (Ethical reference: BE336/05) who consented to genetic screening were included in this study. The study design, the randomization process and the risk factor profile of this sample have been previously published. Briefly, the PLP was a cross-sectional study (conducted from January 2007 to December 2008) of 1428 South African Indians (aged 15 to 64 yr) living in the cadastral area of Phoenix, Durban, South Africa. Participants for the PLP were selected randomly from the previous population census, and using the Kish method, one participant from each home was selected.

Where written consent to participate was obtained, and before the test days, specially trained fieldworkers interviewed participants and all demographic data (sex, age, education and income level, including physical activity, diet, smoking habits, alcohol consumption, history of diabetes mellitus, hypertension) and cardiovascular risk factors were recorded in the STEPS instrument for non-communicable disease (NCD) risk factors, a modified version 1.4. The genetic study protocol was reviewed by the Biomedical Research Ethics Committee, University of Kwa-Zulu Natal, South Africa (Ethical reference: BE232/010).

**Study population:** A total of 999 South African Indians (mean age: 45.4±13.1 yr), comprising 749 females (mean age: 46.0±12.3 yr) and 250 males (43.4±15.2 yr), who consented to genetic screening were enrolled in this study. Anthropometric, physiological and biochemical parameters were recorded in the STEPS instrument for NCD risk factors (version 1.4). The clinical evaluation was conducted at the Lifestyle Centre, Inkosi Albert Luthuli Central Hospital, Durban, South Africa. Anthropometric measurements included waist circumference, weight and height (as per the WHO criteria). Blood pressure (BP) readings were recorded at two-minute intervals (average of three readings was recorded). Systemic hypertension was diagnosed if individuals reported hypertension and/or had readings >140 and >90 mmHg and/or on antihypertensive therapy. After an overnight fast, venous blood (20 ml) was drawn for measuring serum lipid [total triglyceride, high-density lipoprotein cholesterol (HDL-C) and total cholesterol], serum insulin and plasma glucose levels. Plasma insulin was measured by immunoassay, and glucose oxidase method was used to measure fasting plasma glucose. Blood samples (20 ml) for the genetic analysis (Roche, South Africa) were collected in ethylenediaminetetraacetic acid tubes (EDTA).

The diagnosis of the MetS was in accordance with the harmonized definition using the ethnic-specific cut-offs for waist circumference in Asian participants. Participants with the MetS have ≥3 of 5 metabolic risk factors, viz. (i) central obesity: waist circumference ≥90 cm in males or ≥80 cm in females; (ii) triglycerides: ≥150 mg/dl; (iii) HDL-C: <40 mg/dl in males or <50 mg/dl in females; (iv) BP: ≥130/85 mmHg; and (v) fasting blood glucose: ≥100 mg/dl.

**DNA extraction:** Genomic DNA was extracted from whole blood using the MagNA Pure Instrument and a MagNA Pure LC Total Nucleic Acid Isolation Kit according to the manufacturer’s instructions (Roche, South Africa). Briefly, 200 μl of whole blood was transferred to the sample cartridge and loaded onto the MagNA Pure LC workstation together with the necessary disposables and kit reagents. The MagNA Pure LC (Roche, South Africa) used magnetic bead technology and automatically performed the isolation and purification steps, binding of DNA, washing steps and elution of the nucleic acid. DNA concentrations were then determined using the NanoDrop 1000 analyzer (Thermo Scientific, USA) and samples were standardized to 5 ng/μl.

**Selection and genotyping of polymorphisms:** Six SNPs related to lipid metabolism (apolipoprotein Q139X - rs121917821), IR [cholesterol ester transfer protein Taq1B - rs708272; lipoprotein lipase (LPL) Hinf I - rs328; paraoxonase 1 192Arg/Gln - rs662] and obesity (leptin 25CAG - rs104894023; adiponectin 45T>G - rs2241766) were selected. Gene SNPs chosen were relevant to lipid metabolism and the risk for the MetS. The SNP database (dnSNP) at NCBI (http://www.ncbi.nlm.nih.gov/snp) was used. The selection of selected SNPs was based on the following: (i) In a study of 200 participants with an allelic frequency of <0.25 per cent, the apolipoproteinA5 (APOA5) Q139X
showed significant associations with dyslipidaemia. Asian Indians in South Africa have been shown to have a high prevalence of dyslipidaemia. We predicted that the APOA5 Q139X SNP may be related to an increased risk of dyslipidaemia and thereby the MetS. (ii) The LPL (lipoprotein lipase) HinfI SNP has been linked with increased lipolytic activity and dyslipidaemia. Since the allelic frequency for the LPL HinfI varied amongst different ethnicities and this SNP had been examined in South African Indians with myocardial infarction (MI), we hypothesized that this SNP might be related to an increased risk of the MetS in Asian Indians. (iii) The high prevalence of an atherogenic lipid profile and diabetes amongst Asian Indians suggested a possible genetic risk for the MetS. We selected the PON1 (paraoxonase 1) SNPs since the 192Arg allele has been shown to be associated with paraoxonase 1 activity and varying affinity for HDL. (iv) In Asian individuals, the ADP (adiponectin) +45T allele has been found to be associated with IR, which is known to be the driving factor for the MetS. We, therefore, investigated whether the +45T>G SNP was associated with the MetS in our sample. (v) In keeping with other studies on Asian Indians, our previous study showed that obesity was a driving factor for the MetS in our sample. We selected the leptin (LEP) 25CAG SNP since it has been shown to be associated with obesity.

**Genotyping**

Genotyping of the selected SNPs was carried out using polymerase chain reaction (PCR) (probe-specific) on the LightCycler 480 (Roche, South Africa). Amplification of the genomic DNA was obtained using a 13 μl volume, which contained PCR grade water (Roche), genotyping master mix (Roche), forward and reverse primers, forward and reverse probes (Roche), MgCl₂ (where necessary) and 5 μl genomic DNA template. Primer and probe [designed by Roche, South Africa, using the LC Probe Design Software 2.0. using a reference sequence for each of the selected genes from OMIM (https://www.omim.org)] sequences are shown in Table I.

PCR occurred by denaturation at 95°C for 10 sec, annealing at 55°C for 10 sec and extension/elongation at 72°C for 10 sec. On completion of the amplification, a melting curve step occurred by cooling and reheating the PCR mix at 45°C and 95°C, respectively. Final cooling occurred for each PCR mix at 40°C for 30 sec. The integrity of the PCR products was checked in five per cent of randomly selected samples by standard techniques using the Illustra GFX PCR DNA and gel band purification kit (GE Healthcare, Illinois, USA). Purified PCR products were run on a 1.5 per cent agarose gel and visualized using GelVue UV Transilluminator (SynGene, London, UK). To confirm the PCR findings, sequencing was performed on five per cent of the samples using the Sanger method by standard techniques.

**Power calculation:** A minimum f of 0.1 was detected with a sample size of 999 participants with 5 per cent

| Table I. Primer and probe sequences for studied gene polymorphisms |
|----------------------|----------------------|----------------------|
| Gene SNPs            | Primer sequence (5’-3’) | Probe sequence (5’-3’) |
|----------------------|----------------------|----------------------|
| Apolipoprotein A5 Q139X | F: AgCCCTACATggCAgAg | P1: LC640-CCTACTCCATCAgATCCATCgTgTAgg-PH |
|                      | R: TgggCCTTggTgTCTTC | P2: TCCTgCACgCgCAggC-FL |
| CETP Taq1B           | F: TggTgAgAAggTCCTAgC | P1: CCCAgAAACATgggTgTCAgAT-FL |
|                      | R: CCAAAATACACACCACTCTAAT | P2: LC640-ggTTCAgATCTgAgCACAggTTAgg-PH |
| Lipoprotein lipase HinfI | F: TTCTgTTCTAggAgAAAgTgT | P1: LC640-ATTCgAaGACTTgCACAgATCCTgAATTCCACTACATCCg-PH |
|                      | R: CATgAAgCTgCTCTgCTTATA | P2: AATgCTCTACCgACCTCTCCT-FL |
| Paraoxonase 1 192Arg/Gln | F: TATTgTTgTgTggACCT | P1: LC640-CCCAAATACATCCCTACCgATCCgAGAGTCgTCTCA-FL |
|                      | R: ACATACTgCCATCAAgg | P2: CTTggACTATgAgAACCACCgACCAgCTA-FL |
| Leptin 25            | F: TTGTGGCTTgTgACCCTA | P1: LC640-5TTTTCTgTgACgtgTTGGACTCTTGAGGg-FL |
| CAG                  | R: GATCTGGTGGCAATTCTTCT | P2: GATCTGGTGGCAATTCTTCTGAGGAGG-FL |
| Adiponectin 45T>G     | F: gCTggAgCTgTTTACT | P1: LC640-ggTTTTgTTgTgACTgCCg-FL |
|                      | R: gCCATCTTgCCATCAC | P2: AggACTTCCgAgCCTGAgTgTC-FL |

SNPs, single-nucleotide polymorphisms; F, forward primers; R, reverse primers; P1, probe 1; P2, probe 2; CETP, cholesteryl ester transfer protein
significance and 90 per cent power. When HWE holds, \( \chi^2 \) has a Chi-square distribution with 1 df. When HWE does not hold, \( \chi^2 \) has a non-central Chi-square distribution with non-centrality parameter \( n_f^2 \). The cut-off for significance at the 5 per cent level of Chi-square with 1 df was 3.84. Thus, \( P \) value was <0.05 if a test statistic greater than 3.84 was observed. To be at least 90 per cent sure of rejecting HWE, when HWE was false, the non-centrality parameter should be at least 10.51.

**Statistical analysis:** Data were analyzed using the Stata 13.0 (StataCorp LP, USA). The frequencies for the studied SNPs were calculated by gene counting, and the Pearson Chi-square (\( \chi^2 \)) test was used to identify departure from Hardy-Weinberg equilibrium (HWE). The Pearson \( \chi^2 \) test was also used to test associations between independent categorical variables and MetS. If an expected cell count contained fewer than five observations, then the Fisher’s exact test was employed. Difference by means of MetS components and SNPs was assessed using one-way analysis of variance (ANOVA). If the data were not normal, then the Kruskal-Wallis test was used. Adjustment for multiple testing was performed using the Bonferroni correction (calculated using “qqvalue” ado in Stata 13.0). Bivariate and multivariable ordered logistic regression analyses were performed to assess the association of various MetS parameters with the observed genotypes among MetS versus non-MetS individuals.

**Results**

There was a high prevalence of MetS (49.0%) with a slightly higher prevalence in females (n=382/749, 51.0%) than males (n=107/250, 42.8%). The most frequent risk factor components in participants with the MetS were increased waist circumference (95.0%) and elevated triglycerides (71.1%). Increased waist circumference was also present in 61.7 per cent of individuals without MetS (Table II). The prevalence of increased triglyceride was 5.5-fold and fasting blood glucose 7.4-fold in those with MetS.

The genotype distributions of the six SNPs were in HWE, except the LPL Hinf I which deviated from HWE (Table III). Comparison of genotype and allele distribution revealed that none of the studied SNPs were significantly associated with the MetS (Table IV). The risk factor components of the MetS for all participants were compared with the genotypes of the six SNPs (Table V). In addition, the MetS risk factor components were compared with the genotype/allele of the six SNPs in males and in females to look for gender associations (Table VI). The 45T>G SNP of adiponectin was associated with reduced HDL-C levels in male participants with the MetS (\( P=0.001 \)). These findings remain significant on adjusted analysis. The 192Arg/Gln SNP of human paraoxonase 1 was associated with elevated systolic BP in male participants with the MetS (\( P=0.018 \)) (Table VI), but this significance fell away on adjusted analysis. No genotype/gender associations were observed in females. Similarly, no associations between the MetS risk factors with genotypes amongst MetS participants were observed (Table VII).

**Discussion**

In this study of Asian Indians, no genetic predisposition to the MetS was observed for the selected SNPs. While studies performed in South Asians have shown positive associations between the FABP2 A4a54Thr\( ^{20} \), APOCIII T-455C and APOCIII C-482T\( ^{21} \), APOA1 T655C, APOA1 T756C and APOA1 T1001C SNPs\( ^{22} \) and the MetS, only a few studies have

| Variables | No MetS (n=483) n (%) | MetS (n=516) n (%) | OR | CI | P |
|-----------|----------------------|-------------------|----|----|---|
| WC ≥80 cm (females); 90 cm (males) | 298 (61.7) | 490 (95.0) | 11.700 | 7.572-18.076 | <0.001 |
| Systolic blood pressure ≥130 mmHg | 115 (23.8) | 335 (64.9) | 5.922 | 4.491-7.810 | <0.001 |
| Diastolic blood pressure ≥85 mmHg | 82 (17.0) | 270 (52.3) | 5.367 | 4.001-7.200 | <0.001 |
| Fasting blood glucose ≥100 mg/dl | 30 (6.2) | 238 (46.1) | 12.927 | 8.596-19.441 | <0.001 |
| Triglycerides ≥150 mg/dl | 63 (13.0) | 367 (71.1) | 16.421 | 11.851-22.752 | <0.001 |
| HDL-C<50 mg/dl (females); <40 mg/dl (males) | 106 (21.9) | 344 (66.7) | 7.113 | 5.361-9.437 | <0.001 |

The main drivers for the MetS were increased levels of serum triglyceride, fasting blood glucose and waist circumference. WC, waist circumference; OR, odds ratio; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol
Gene polymorphisms related to metabolic syndrome have been performed in Asian Indians. Studies that have examined the IRS-1 G-972R, PPAR-Gamma P12A, PPAR-Gamma KCNJIIE23K, TNF-Alpha-308G/A, PPAR-Gamma C1A and PPAR-Gamma UCP1 have failed to show any association with the MetS.

Associations have been described between the selected candidate gene SNPs and IR. For example, carriers of the CETP Taq1B in Spanish and the adiponectin 45T>G (+45T allele) in Taiwanese have been associated with IR. This is probable since IR is the driving factor for the development of the MetS.

Our study was adequately powered to detect differences in genotype frequencies. It should be noted that studies showing positive associations between the SNPs we studied and the MetS have been performed on <100 study samples compared to ours. For example, the APOA5 Q139X SNP was evaluated in nine White participants, the LPL Hinfl in 99 Caucasians and the leptin 25CAG in 30 Thai participants. It is also possible that population stratification could have been a confounding factor, leading to false-positive findings in studies with small samples.

A low prevalence of the MetS has been described in Singapore Indians (20.9% of males and 15.5% of females) and in Indians from Mauritius (10.6% in males and 14.7% in females). Our findings were in keeping with high prevalence described in European Asian Indians (46.0% of males and 38.0% of females) and in Canadian Indians (41.6%) and support the report of a 60 per cent prevalence of the MetS in a sample of South African Indians with MI, indicating a high cardiovascular risk in this community.

We considered other possibilities to explain the negative findings in our study. It was unlikely that our sample was skewed since all but LPL Hinfl were in HWE. The deviation for the LPL Hinfl SNP (P<0.05) could be explained by one or more assumptions. For example, population stratification and non-random mating may be possible. Finally, genotyping errors, i.e. ‘null alleles’ being present resulting in false observation of homozygotes, could account for deviation from HWE. Furthermore, sequencing was performed in five per cent of samples to ensure the accuracy of our findings.

In our sample, females had a higher prevalence of the MetS compared to males. Although we had fewer males in our study, our finding could be true since the female gender predisposition was also shown in one other South African study. In contrast, Chow et al.
in Southern India showed that males were at a greater risk for the MetS than females (26.9 vs 18.4%). While these gender differences could be due to the different gender ethnic-specific cut-offs in the criteria for the MetS, environmental changes and sedentary lifestyles could also have contributed to the cardiometabolic risk factor profiles and the observed gender differences in prevalence of the MetS.

Table IV. Genotype/allele frequencies in individuals with and without metabolic syndrome (MetS)

| SNP         | Genotype | MetS, n (%) | No MetS, n (%) | $P^*$ | $P^\dagger$ |
|-------------|----------|-------------|----------------|-------|------------|
| APOA5 Q139X | n (%)*   | 489 (48.9)  | 510 (51.1)     | -     | -          |
|             | CC       | 489 (100)   | 510 (100)      |       |            |
|             | TT       | 0           | 0              |       |            |
|             | CT       | 0           | 0              |       |            |
|             | C-allele | 978 (100)   | 1020 (100)     |       |            |
|             | T-allele | 0           | 0              |       |            |
| LPL Hinfl   | n (%)*   | 489 (48.9)  | 510 (51.1)     | 0.59  | 0.99       |
|             | CC       | 372 (48.2)  | 400 (51.8)     |       |            |
|             | GG       | 29 (54.7)   | 24 (45.3)      |       |            |
|             | CG       | 88 (50.6)   | 86 (49.4)      |       |            |
|             | C-allele | 832 (48.4)  | 886 (51.6)     |       |            |
|             | G-allele | 146 (52.1)  | 134 (47.9)     |       |            |
| PON1 192 Arg/Gln | n (%)*  | 489 (48.9)  | 510 (51.1)     | 0.54  | 0.99       |
|             | AA       | 273 (50.5)  | 268 (49.5)     |       |            |
|             | GG       | 26 (44.8)   | 32 (55.2)      |       |            |
|             | AG       | 190 (47.5)  | 210 (52.5)     |       |            |
|             | A-allele | 736 (49.7)  | 746 (50.3)     |       |            |
|             | G-allele | 242 (46.9)  | 274 (53.1)     |       |            |
| CETP Taq1B  | n (%)*   | 489 (48.9)  | 510 (51.1)     | 0.76  | 0.99       |
|             | GG       | 151 (48.6)  | 160 (51.4)     |       |            |
|             | AA       | 114 (51.1)  | 109 (48.9)     |       |            |
|             | GA       | 224 (48.2)  | 241 (51.8)     |       |            |
|             | G-allele | 526 (48.4)  | 561 (51.6)     |       |            |
|             | A-allele | 452 (49.6)  | 459 (50.4)     |       |            |
| ADP 45T>G   | n (%)*   | 489 (48.9)  | 510 (51.1)     | 0.17  | 0.97       |
|             | TT       | 364 (48.9)  | 381 (51.1)     |       |            |
|             | GG       | 5 (27.8)    | 13 (72.2)      |       |            |
|             | TG       | 120 (50.8)  | 116 (49.2)     |       |            |
|             | T-allele | 848 (49.1)  | 878 (50.9)     |       |            |
|             | G-allele | 130 (47.8)  | 142 (52.2)     |       |            |
| LEP 25CAG   | n (%)*   | 489 (48.9)  | 510 (51.1)     | 0.52  | 0.99       |
|             | AA       | 486 (49.0)  | 505 (51.0)     |       |            |
|             | GG       | 0           | 0              |       |            |
|             | AG       | 3 (37.5)    | 5 (62.5)       |       |            |
|             | A-allele | 975 (49.0)  | 1015 (51.0)    |       |            |
|             | G-allele | 3 (37.5)    | 5 (62.5)       |       |            |

$\chi^2$: $P^*$, Both unadjusted and $P^\dagger$, Bonferroni adjusted; * No mutation in sample.
None of the studied SNPs increased the risk for the MetS. APOA5, apolipoprotein A5; LPL, lipoprotein lipase; PON1, human paraoxonase 1; ADP, adiponectin; LEP, leptin; CETP, cholesteryl ester transfer protein; SNP, single nucleotide polymorphism
Central obesity (waist circumference) (95.0%) and hypertriglyceridaemia (71.1%) were found to occur more frequently in our participants. This has been attributed to the effects of high blood glucose on lipid metabolism, resulting in hypertriglyceridaemia and obesity. The high prevalence of increased triglyceride and fasting blood glucose with the MetS suggests that risk factor clustering in our participants may be related more to obesity and diabetes than to a genetic predisposition to the MetS.

Although there was no association with the selected gene SNPs with the MetS, certain genotypes were associated with specific risk factor components of the MetS. Males diagnosed with MetS with the human paraoxonase 1 192Arg/Gln (AA genotype) were more inclined to have elevated systolic BP. It has been postulated that participants with this genotype who have hypertension may possibly have increased oxidative stress that alters the functioning of paraoxonase, leading to endothelial dysfunction and predisposition to the MetS. More studies in this population are needed.

### Table V. Association between gene polymorphisms and metabolic components

| Gene polymorphism | Metabolic components | Mean±SD | P∞ | P‡ |
|-------------------|----------------------|---------|----|----|
| WTH genotype | | | | |
| MH genotype | | | | |
| HET genotype | | | | |

**PON1 192Arg/Gln**
- Waist circumference (cm)
  - 95.8±15.0
  - 96.2±14.3
  - 95.1±15.9
  - 0.770
  - 0.993
- Systolic pressure (mmHg)
  - 128.7±24.3
  - 126.7±21.0
  - 128.8±23.4
  - 0.810
  - 0.993
- Diastolic pressure (mmHg)
  - 81.3±12.9
  - 79.6±10.8
  - 79.8±12.2
  - 0.160
  - 0.968
- Blood glucose (mg/dl)
  - 111.7±52.3
  - 122.5±57.7
  - 111.7±77.5
  - 0.430
  - 0.993
- Triglycerides (mg/dl)
  - 159.4±106.3
  - 150.6±70.9
  - 159.4±106.3
  - 0.590
  - 0.993
- HDL-C (mg/dl)
  - 58.0±131.5
  - 50.3±11.6
  - 50.3±23.2
  - 0.400
  - 0.900

**CETP Taq1B**
- Waist circumference (cm)
  - 95.5±15.2
  - 95.2±14.2
  - 95.7±15.9
  - 0.910
  - 0.996
- Systolic pressure (mmHg)
  - 129.0±24.2
  - 129.4±23.2
  - 128.0±23.7
  - 0.720
  - 0.993
- Diastolic pressure (mmHg)
  - 81.1±13.1
  - 81.9±12.2
  - 79.7±12.2
  - 0.080
  - 0.968
- Blood glucose (mg/dl)
  - 109.9±50.5
  - 120.7±100.9
  - 108.1±46.8
  - 0.060* 0.917
- Triglycerides (mg/dl)
  - 150.6±88.6
  - 168.3±124.0
  - 159.4±106.3
  - 0.210
  - 0.968
- HDL-C (mg/dl)
  - 50.3±19.3
  - 69.6±197.2
  - 50.3±27.1
  - 0.170
  - 0.946

**ADP 45T>G**
- Waist circumference (cm)
  - 95.3±15.8
  - 92.1±11.7
  - 96.4±13.8
  - 0.410
  - 0.993
- Systolic pressure (mmHg)
  - 129.3±23.6
  - 121.7±19.4
  - 126.9±24.4
  - 0.180
  - 0.968
- Diastolic pressure (mmHg)
  - 80.9±12.4
  - 76.3±10.1
  - 80.2±13.0
  - 0.250
  - 0.993
- Blood glucose (mg/dl)
  - 111.7±68.5
  - 97.3±23.4
  - 108.1±46.8
  - 0.600
  - 0.993
- Triglycerides (mg/dl)
  - 159.4±106.3
  - 124.0±79.7
  - 168.3±106.3
  - 0.320
  - 0.993
- HDL-C (mg/dl)
  - 54.1±27.1
  - 46.4±11.6
  - 61.9±201.1
  - 0.320
  - 0.993

**LEP 25CAG**
- Waist circumference (cm)
  - 95.5±15.3
  - -
  - 102.8±10.8
  - 0.180
  - 0.968
- Systolic pressure (mmHg)
  - 128.6±23.7
  - -
  - 126.6±27.3
  - 0.810
  - 0.993
- Diastolic pressure (mmHg)
  - 80.6±12.6
  - -
  - 80.4±6.8
  - 0.960
  - 0.997
- Blood glucose (mg/dl)
  - 111.7±64.9
  - -
  - 106.3±25.2
  - 0.780
  - 0.993
- Triglycerides (mg/dl)
  - 159.4±106.3
  - -
  - 124.0±35.4
  - 0.310
  - 0.993
- HDL-C (mg/dl)
  - 54.1±96.7
  - -
  - 50.3±11.6
  - 0.870
  - 0.993

*ANOVA unadjusted P; †Bonferroni adjusted P value; The Pearson $\chi^2$ or Fishers exact test was employed given the categorical nature of the variables; -, No mutant homozygotes.

The $P$ values are calculated within the MetS only group and also only within non-MetS group. On unadjusted analysis LPL HinfI GG and CETP Taq1B AA were marginally associated with elevated diastolic blood pressure and blood glucose levels respectively ($P=0.06$). No associations were demonstrated on the adjusted analysis. Because the APOA5 Q139X was monomorphic and the LPL Hinf1 did not follow HWE, these were excluded from the analysis. APOA5, apolipoprotein A5; LPL, lipoprotein lipase; PON1, human paraoxonase 1; CETP, cholesteryl ester transfer protein; ADP, adiponectin; LEP, leptin; WTH, wild type homozygotes; MH, mutant homozygotes; HET, heterozygotes; HDL-C, high-density lipoprotein cholesterol; SD, standard deviation; ANOVA, analysis of variance; MetS, metabolic syndrome.
required to further examine the association of this SNP with MetS.

The adiponectin 45T>G SNP has been shown to be positively associated with the MetS in 151 Uygur Asians. Although no such association was found in our study, it was observed that males diagnosed with MetS with the adiponectin 45T>G were more inclined to have reduced HDL-C levels. Larger studies are required to confirm whether the adiponectin 45T>G confers a greater risk for dyslipidaemia in male participants, in this way predisposing them to the MetS.

There are several limitations of this study that need to be considered. First, the discrepancies in associations between the SNPs and the MetS may possibly be related to the sample studied which comprised a larger number of females. This investigation used cross-sectional data, which provided information on a once-off basis and were limited by the lack of a longitudinal analysis which could contribute immensely to the understanding of the MetS and its association with genetic factors in Asian Indians. Second, the study examined specific SNPs related to lipid metabolism and to obesity; we did not genotype other SNPs known to be associated with MetS.

Table VI. Genotype associations in males with metabolic syndrome (MetS)

| SNP          | Metabolic risk factors | MetS                  | P<sub><sup>∞</sup></sub> | P<sub><sup>‡</sup></sub> |
|--------------|------------------------|-----------------------|--------------------------|--------------------------|
|              | Wild-type homozygote   | Mutant homozygote     | Heterozygote             |                          |
| PON1 192Arg/Gln | Waist circumference (cm) | 97.0±9.3              | 102.4±13.6               | 101.0±10.1               | 0.097  | 0.980                  |
|              | Systolic pressure (mmHg) | 143.8±19.8            | 124.0±37.3               | 133.1±22.1               | 0.018* | 0.860                  |
|              | Diastolic pressure (mmHg) | 88.5±12.5             | 78.8±17.3                | 86.2±11.1                | 0.197  | 0.980                  |
|              | Blood glucose (mg/dl)   | 120.7±46.8            | 147.7±61.3               | 126.1±50.5               | 0.440  | 0.993                  |
|              | Triglycerides (mg/dl)   | 230.3±124.0           | 203.7±53.1               | 239.1±97.4               | 0.774  | 0.993                  |
|              | HDL-C (mg/dl)           | 38.7±7.7              | 42.5±7.7                 | 38.7±7.7                 | 0.266  | 0.993                  |
| CETP Taq1B   | Waist circumference (cm) | 101.1±9.2             | 95.1±9.6                 | 99.5±10.2                | 0.067  | 0.980                  |
|              | Systolic pressure (mmHg) | 140.4±28.4            | 135.0±19.0               | 139.3±19.8               | 0.638  | 0.993                  |
|              | Diastolic pressure (mmHg) | 87.8±12.6             | 87.4±10.5                | 86.5±13.0                | 0.898  | 0.993                  |
|              | Blood glucose (mg/dl)   | 118.9±55.9            | 138.7±43.2               | 118.9±43.2               | 0.241  | 0.993                  |
|              | Triglycerides (mg/dl)   | 221.4±88.6            | 256.9±115.1              | 230.3±124.0              | 0.480  | 0.993                  |
|              | HDL-C (mg/dl)           | 38.7±7.7              | 42.5±11.6                | 38.7±7.7                 | 0.103  | 0.980                  |
| ADP 45T>G    | Waist circumference (cm) | 99.4±9.6              | 96.9±11.2                | 96.9±11.2                | 0.301  | 0.993                  |
|              | Systolic pressure (mmHg) | 140.2±21.8            | 132.4±23.8               | 132.4±23.8               | 0.144  | 0.980                  |
|              | Diastolic pressure (mmHg) | 87.0±12.1             | 87.6±13.2                | 87.6±13.2                | 0.817  | 0.993                  |
|              | Blood glucose (mg/dl)   | 124.3±52.3            | 120.7±39.6               | 120.7±39.6               | 0.694  | 0.993                  |
|              | Triglycerides (mg/dl)   | 230.3±115.1           | 248.0±88.6               | 248.0±88.6               | 0.652  | 0.993                  |
|              | HDL-C (mg/dl)           | 38.7±7.7              | 42.5±7.7                 | 42.5±7.7                 | 0.001* | 0.001*                 |
| LEP 25CAG    | Waist circumference (cm) | 98.9±9.9              | -                        | -                        | -      | -                      |
|              | Systolic pressure (mmHg) | 138.6±22.3            | -                        | -                        | -      | -                      |
|              | Diastolic pressure (mmHg) | 87.1±12.2             | -                        | -                        | -      | -                      |
|              | Blood glucose (mg/dl)   | 124.3±48.6            | -                        | -                        | -      | -                      |
|              | Triglycerides (mg/dl)   | 239.1±115.1           | -                        | -                        | -      | -                      |
|              | HDL-C (mg/dl)           | 38.7±7.7              | -                        | -                        | -      | -                      |

*ANOVA unadjusted P; †Bonferroni adjusted P value. Two P values are presented (one unadjusted for multiple testing and one adjusted for multiple testing) based on comparison of mean values within the MetS group and separately for within non-MetS group. The PON1 192Arg/Gln AA and the ADP 45T>G TT was associated with elevated systolic blood pressure and reduced HDL-C levels, respectively. Because the APOA5 Q139X was monomorphic and the LPL Hinf 1 did not follow HWE, both were excluded from the analysis. APOA5, apolipoprotein A5; LPL, lipoprotein lipase; PON1, paraoxonase 1; CETP, cholesteryl ester transfer protein; ADP, adiponectin; LEP, leptin; ANOVA, analysis of variance; HDL-C, high-density lipoprotein cholesterol.
| Gene SNP | metabolic risk factors harmonized | MetS | OR     | 95% CI        | P     |
|---------|----------------------------------|------|--------|--------------|-------|
| *PON1* 192Arg/Gln | WC ≥80 cm (females); 90 cm (males) | 1.005 | 0.990-1.019 | 0.341 |
|         | Systolic blood pressure ≥130 mmHg | 0.996 | 0.987-1.006 |       |
|         | Diastolic blood pressure ≥85 mmHg | 0.992 | 0.974-1.010 |       |
|         | Fasting blood glucose ≥100 mg/dl  | 1.031 | 0.988-1.076 |       |
|         | Triglycerides ≥150 mg/dl          | 0.965 | 0.830-1.122 |       |
|         | HDL-C <50 mg/dl (females); <40 mg/dl (males) | 0.769 | 0.535-1.183 |       |
|         | Age                               | 1.010 | 0.992-1.027 |       |
|         | Gender                            | 1.047 | 0.672-1.630 |       |
| *CETP* Taq1B | WC ≥80 cm (females); 90 cm (males) | 1.005 | 0.992-1.019 | 0.352 |
|         | Systolic blood pressure ≥130 mmHg | 1.001 | 0.992-1.010 |       |
|         | Diastolic blood pressure ≥85 mmHg | 1.001 | 0.984-1.018 |       |
|         | Fasting blood glucose ≥100 mg/dl  | 0.974 | 0.932-1.018 |       |
|         | Triglycerides ≥150 mg/dl          | 0.924 | 0.808-1.057 |       |
|         | HDL-C <50 mg/dl (females); <40 mg/dl (males) | 0.786 | 0.535-1.183 |       |
|         | Age                               | 1.003 | 0.987-1.020 |       |
|         | Gender                            | 0.908 | 0.602-1.369 |       |
| *ADP* 45T>G | WC ≥80 cm (females); 90 cm (males) | 1.003 | 0.986-1.019 | 0.466 |
|         | Systolic blood pressure ≥130 mmHg | 1.007 | 0.996-1.018 |       |
|         | Diastolic blood pressure ≥85 mmHg | 0.994 | 0.973-1.015 |       |
|         | Fasting blood glucose ≥100 mg/dl  | 1.014 | 0.962-1.070 |       |
|         | Triglycerides ≥150 mg/dl          | 1.010 | 0.856-1.191 |       |
|         | HDL-C <50 mg/dl (females); <40 mg/dl (males) | 0.972 | 0.923-1.023 |       |
|         | Age                               | 0.982 | 0.961-1.002 |       |
|         | Gender                            | 1.427 | 0.839-2.428 |       |
| *LEP* 25CAG | WC ≥80 cm (females); 90 cm (males) | 1.030 | 0.972-1.092 | 0.396 |
|         | Systolic blood pressure ≥130 mmHg | 1.045 | 0.976-1.119 |       |
|         | Diastolic blood pressure ≥85 mmHg | 0.972 | 0.850-1.112 |       |
|         | Fasting blood glucose ≥100 mg/dl  | 0.930 | 0.594-1.456 |       |
|         | Triglycerides ≥150 mg/dl          | 0.429 | 0.084-2.186 |       |
|         | HDL-C <50 mg/dl (females); <40 mg/dl (males) | 1.030 | 0.613-1.735 |       |
|         | Age                               | 1.135 | 0.990-1.302 |       |
|         | Gender                            | 1.990 | 0.0-0   |       |

No associations between the MetS risk factors with genotypes among MetS participants were observed. Because the *APOA5* Q139X was monomorphic and the LPL Hinf 1 did not follow HWE, both were excluded from the analysis. *APOA5*, apolipoprotein A5; *LPL*, lipoprotein lipase; *PON1*, human paraoxonase 1; GENO, genotype; CETP, cholesteryl ester transfer protein; *ADP*, adiponectin; *LEP*, leptin; SNP, single nucleotide polymorphism; MetS, metabolic syndrome; WC, waist circumference; OR, odds ratio; CI, confidence interval; Age/gender included as confounders.
lipid metabolism (such as FABP2 Ala54Thr\textsuperscript{28}; APOA1 T655C, T756C, T1001C\textsuperscript{22}), but the selected SNPs were chosen on the basis of previous studies\textsuperscript{8,10,17,18}. Because of the high prevalence of diabetes in this sample, SNPs in genes associated with MetS that affect glucose metabolism such as TCF7L2\textsuperscript{35} and PPARGamma\textsuperscript{23,24} are likely to yield more positive associations with the MetS. Third, there was a lack of haplotype analysis in this study and replicating these findings and testing for haplotypes associated with the risk for the MetS might prove valuable. The sample size for interaction-type analysis between the single locus did not reveal any significant findings which may be partially explained by the genotype/allele frequencies of the participants studied.

In conclusion, our study showed a high prevalence of the MetS in the studied population, however, no genetic predisposition to the MetS based on the studied SNPs was demonstrated. This suggests that the absolute genetic risk for the MetS is probably small and possibly lies in the component risk factors of the MetS. In view of the association with risk factor components, the adiponectin 45T>G and the human paraoxonase 1 192Arg/Gln SNPs in male participants may predispose to dyslipidaemia and hypertension, respectively. Future studies addressing gene-environmental influences are more likely to identify predisposition to the MetS.

Financial support & sponsorship: The research was financially supported by the WHO, Pfizer Laboratory (SA), and the South African Centre for Epidemiological Modelling and Analysis (SACEMA), South Africa.

Conflicts of Interest: None.

References
1. Misra A, Khurana L. The metabolic syndrome in South Asians: Epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009; 7 : 497-514.
2. Sawant A, Mankeshwar R, Shah S, Raghavan R, Dhongde G, Raje H, et al. Prevalence of metabolic syndrome in urban India. Cholesterol 2011; 2011 : 1-7.
3. Groop L. Genetics of the metabolic syndrome. Br J Nutr 2000; 83 (Suppl 1) : S39-48.
4. Langefeld CD, Wagenknecht LE, Rotter JI, Williams AH, Hokanson JE, Saad MF, et al. Linkage of the metabolic syndrome to 1q23-q31 in Hispanic families: The insulin resistance atherosclerosis study family study. Diabetes 2004; 53 : 1170-4.
5. Niculescu LS, Fruchart-Najib J, Fruchart JC, Sima A. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome. Clin Chem Lab Med 2007; 45 : 1133-9.
6. Ranjith N, Pegoraro RJ, Shannugam R. Obesity-associated genetic variants in young Asian Indians with the metabolic syndrome and myocardial infarction. Cardiovasc J Afr 2011; 22 : 25-30.
7. Prakashchandra DR, Esterhuizen TM, Motala AA, Gathirim P, Naidoo DP. High prevalence of cardiovascular risk factors in Durban South African Indians: The Phoenix lifestyle project. S Afr Med J 2016; 106 : 284-9.
8. World Health Organization. WHO STEPwise approach to surveillance instrument v.1.4. Geneva: World Health Organization; 2003.
9. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120 : 1640-5.
10. Marçais C, Verges B, Charrière S, Pruneta V, Merlin M, Billon S, et al. ApoA5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 2005; 115 : 2862-9.
11. Ross CJ, Liu G, Kuivenhoven JA, Twisk J, Rip J, van Dop W, et al. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol 2005; 25 : 2143-50.
12. Mattu RK, Needham EW, Morgan R, Rees A, Hackshaw AK, Stocks J, et al. DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. Arterioscler Thromb 1994; 14 : 1090-7.
13. Huang X, Gong R, Lin J, Li R, Xiao L, Duan W, et al. Effects of lipoprotein lipase gene variations, a high-carbohydrate low-fat diet, and gender on serum lipid profiles in healthy Chinese Han youth. Biosci Trends 2011; 5 : 198-204.
14. Hughes K, Yeo PPB, Lun KC, Thai AC, Sothy SP, Wang KW, et al. Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. II. Differences in risk factor levels. J Epidemiol Community Health 1990; 44 : 29-35.
15. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299 : 1265-76.
16. Boekholdt SM, Kuivenhoven JA, Hovingh GK, Jukema JW, Kastelein JJ, van Tol A, et al. CETP gene variation: Relation to lipid parameters and cardiovascular risk. Curr Opin Lipidol 2004; 15 : 393-8.
17. Lee YY, Lee NS, Cho YM, Moon MK, Jung HS, Park YJ, et al. Genetic association study of adiponectin polymorphisms with risk of type 2 diabetes mellitus in Korean population. Diabet Med 2005; 22 : 569-75.
18. Siddiquie T, Bhowmik B, Da Vale Moreira NC, Mujumder A, Mahatab H, Khan AK, et al. Prevalence of obesity in a rural Asian Indian (Bangladesh) population and its determinants. BMC Public Health 2015; 15 : 860.
children with early onset obesity. J Med Assoc Thai 2009; 92 (Suppl 7) : S108-14.

20. Guettier JM, Georgopoulos A, Tsai MY, Radha V, Shanthirani S, Deepa R, et al. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab 2005; 90 : 1705-11.

21. Miller M, Rhyne J, Chen H, Beach V, Ericson R, Luthra K, et al. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res 2007; 38 : 444-51.

22. Dodani S, Henkhaus R, Dong L, Butler MG. Apo lipoprotein A1 gene polymorphisms predict cardio-metabolic risk in South Asian immigrants. Dis Markers 2012; 32 : 9-19.

23. Ranjith N, Pegoraro RJ, Naidoo DP, Shanmugam R, Rom L. Genetic variants associated with insulin resistance and metabolic syndrome in young Asian Indians with myocardial infarction. Metab Syndr Relat Disord 2008; 6 : 209-14.

24. Vimaleswaran KS, Radha V, Deepa R, Mohan V. Absence of association with metabolic syndrome with PPARGC1A, PPARG and UCP1 gene polymorphisms in Asian Indians. Metab Syndr Relat Disord 2007; 5 : 153-62.

25. López-Ríos L, Pérez-Jiménez P, Martínez-Quintana E, Rodriguez González G, Díaz-Chico BN, Nóvoa FJ, et al. Association of Taq 1B CETP polymorphism with insulin and HOMA levels in the population of the Canary Islands. Nutr Metab Cardiovasc Dis 2011; 21 : 18-24.

26. Yang WS, Tsou PL, Lee WJ, Tseng DL, Chen CL, Peng CC, et al. Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity. J Mol Med (Berl) 2003; 81 : 428-34.

27. Garenc C, Pérusse L, Gagnon J, Chagnon YC, Bergeron J, Després JP, et al. Linkage and association studies of the lipoprotein lipase gene with postheparin plasma lipase activities, body fat, and plasma lipid and lipoprotein concentrations: The HERITAGE family study. Metabolism 2000; 49 : 432-9.

28. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the national cholesterol education program adult treatment panel definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27 : 1182-6.

29. Cameron AJ, Shaw JE, Zimmet PZ, Chitson P, Alberti KGMM, Tuomilehto J. Comparison of metabolic syndrome definitions in the prediction of diabetes over 5 years in Mauritius. Diabetologia 2003; 46 : A145-6.

30. Unwin N, Bhopal R, Hayes L, White M, Patel S, Ragoobirsingh D, et al. A comparison of the new international diabetes federation definition of metabolic syndrome to WHO and NCEP definitions in Chinese, European and South Asian origin adults. Ethn Dis 2007; 17 : 522-8.

31. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108 : 420-5.

32. Chow CK, Naidu S, Raju K, Raju R, Joshi R, Sullivan D, et al. Significant lipid, adiposity and metabolic abnormalities amongst 4535 Indians from a developing region of rural Andhra Pradesh. Atherosclerosis 2008; 196 : 943-52.

33. Irace C, Cortese C, Fiaschi E, Scavelli F, Liberatoscioli L, Federici G, et al. The influence of PON1 192 polymorphism on endothelial function in diabetic subjects with or without hypertension. Hypertens Res 2008; 31 : 507-13.

34. Li LL, Kang XL, Ran XJ, Wang Y, Wang CH, Huang L, et al. Associations between 457G polymorphism of the adiponectin gene and plasma adiponectin levels with type 2 diabetes. Clin Exp Pharmacol Physiol 2007; 34 : 1287-90.

35. Saadi H, Nagelkerke N, Carruthers SG, Benedict S, Abdulkhalak S, Reed R, et al. Association of TCF7L2 polymorphism with diabetes mellitus, metabolic syndrome, and markers of beta cell function and insulin resistance in a population-based sample of Emirati subjects. Diabetes Res Clin Pract 2008; 80 : 392-8.

For correspondence: Dr Datshana P. Naidoo, Department of Cardiology (Medical School), University of KwaZulu Natal, Private Bag 7, Congella, Durban 4013, South Africa

e-mail: naidood@ukzn.ac.za